News

Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
Alkermes has a huge opportunity to expand its label to include pediatric patients with Schizophrenia and bipolar I disorder.
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight
The schizophrenia market size is expected to grow during the forecast period (2025–2034). DelveInsight’s analysis projects growth in the schizophrenia market, driven by rising disease prevalence, the ...
The Healthy @Reader's Digest on MSN9h
How a Person with Bipolar Disorder Thinks, an Expert Doctor Explains
A Cleveland Clinic psychiatrist discusses what the latest research suggests causes bipolar, what the individual experiences, ...
IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight
DelveInsight's 'IGALMI Market Size, Forecast, and Market Insight Report' highlights the details around IGALMI, a sublingual film formulation ...